Bullpen.News From Edwin Dorsey
Get Daily Recap Feedback

Sunday, September 27, 2026

Back to today

From X

@ActAccordingly 2 clicks

PAA Research on X

Big gap higher pre-mkt for $W. Furniture names in general have been ripping the past 3-months. QUIETLY. 4+ years of brutal housing market headwinds and these businesses have been grinding away, generating cash, buying back stock, preserving margins. Easy comps + the potential of an upturn in housing velocity make it a good recipe for longs with valuations that remain notably cheap relative to mid-cycle EBITDA. Look at some of these 3-month returns: $BOBS: 64.8% $W: 35.8% $BSET: 34.1% $WSM: 33.2% $HOFT: 21.4% $LZB: 18.5% $ETD 12.2% There's plenty of juice in the group with a sustained upturn in home furnishings spend after the post-COVID19 crash. $WSM is on our Buyback Outliers list. I own $BSET, $ETD, $BBBY
@convequity

Convequity on X

Why we exited $FIG AI coding agents and prompt-to-UI tools are changing the design workflow faster than most expected. Platforms such as v0, Lovable and Claude Design can already take a team from idea to a working interface without a traditional design file in the middle. Figma has added its own generative features, yet these have largely been layered on via external model APIs rather than a full re-architecture around AI-native workflows. Newer entrants were built for this environment from the start. In public interviews the founding team has consistently struck a defensive posture — essentially arguing the existing franchise is secure — rather than showing the urgency of a company prepared to disrupt its own model. That mindset is rarely a positive signal when a platform shift is underway. After several quarters of waiting for a more compelling response, we exited the position.
@convequity 1 click

Convequity on X

Why we exited $CRSP and kept $TEM AlphaFold solved the backend of the problem — predicting a protein’s 3D structure from its sequence. The harder frontend problem remains: knowing which protein or pathway is actually worth targeting. Most complex diseases are still poorly understood at the causal level. That distinction matters. The next real breakthroughs look more likely to come from AI-native groups that treat large-scale compute as the primary engine, in the same way OpenAI and Anthropic approached language before the ChatGPT moment. Public investors may only get clean access later via secondaries or IPOs. CRISPR sits on the earlier-generation side of that divide. Tempus is closer to the compute-and-data native side — building models while assembling a genuine clinical data moat. That is why one was exited and the other retained.
@evantindell

Evan Tindell on X

Finally got a chance to go through the $UMG earnings... Obviously, a disappointment on revenue growth and margins, which saw the stock drop like 20%. Subscription revenue was 6.7% organically, and the street was looking for >9%. So, a big miss. Still, I think things should improve. Apple, Spotify, Amazon, and YouTube music have all raised prices this year, and a portion of that will go to UMG. CFO Matt Ellis said on the call that these prices and "better market share to start the third quarter" make them "cautiously optimistic" (really sticking his neck out there!!) that growth will improve in H2 of 2026. Interestingly, Warner Music $WMG managed to grow revenue 12% in CC and adjusted OIBDA by 24%, so clearly this is a UMG-only problem, at least for this quarter. $UMG trades at 14x earnings on a NTM basis now... this seems pretty reasonable if not downright cheap for a company that has grown EBIT from EUR 1b in 2019 to around 2b today (11% organic EBITDA CAGR). We own this through Bollore, which currently has an NAV of just above 11 EUR by my calculation vs a last price of under 4 EUR. Notably, JPM thinks new AI tiers in Spotify and Apple Music will drive ARPU growth of 300 bps per year. Their price target was 48 EUR prior to the recent earnings release...

Investor Letters

All letters

Updates

FGPR remains on track, PRTH's management buyout is set at $8.05, and microcap RAVE is described as cheap.

PRTH $642M
Nat Stewart - Stock Picking Newsletter 13 clicks

Reddit: DCF Valuation

Reddit’s DCF values shares at $225, driven by international ARPU expansion from $2.2 to $8.3 by 2035 and 38% operating margins.

RDDT $29B
Hated Moats 8 clicks
THC · long

Tenet Healthcare CORP

Tenet Healthcare generates roughly two-thirds of profits from hospitals and one-third from ambulatory surgery centers.

THC $21B
Value Investors Club 2 clicks

Publications we follow

Every publication on this site, hand-picked.

109 publications

Newsletters 92

YouTube 4

Blogs 12

Seeking Alpha 44 of 213

Nominate a publication

X accounts we follow

Every account on this site, hand-picked.

73 accounts
Nominate an account

Investor letters we follow

189 firms

Sectors

Ordered by how often our editor reaches for them.